Dr. Alan R Prossin, MD
Claim this profileThe University of Texas Health Science Center at Houston
Studies Postprandial Fullness Syndrome
Studies Neuropsychiatric Disorders
3 reported clinical trials
6 drugs studied
Affiliated Hospitals
Clinical Trials Alan R Prossin, MD is currently running
Anti-Inflammatory Drug + Pain Challenge
for Pain
The first objective of the study is to evaluate whether a novel bio-signature (derived from a wide range of pro- and anti-nociceptive IL-1 family cytokine activity) will predict pain experienced and also release of underlying endogenous opioid neurotransmitters during an experimental nociceptive pain challenge, which will be performed while simultaneously quantifying mu-opioid receptor activity in the brain via \[11C\]-carfentanil PET neuroimaging in healthy subjects. Another objective is to evaluate whether an anti-inflammatory drug that reduces activation of IL-1b (minocycline) will perturb the balance between pro- and anti-nociceptive IL-1 cytokines and effect a reduction in pain experienced (and endogenous opioids released) during the experimental, nociceptive pain challenge. A final objective is to evaluate performance characteristics (sensitivity, accuracy, dynamic range) of the biosignature for the purpose of predicting post-operative pain.
Recruiting0 awards Phase 13 criteria
PET Imaging
for Neuropsychiatric Disorders
The purpose of this research is to determine whether there is more extensive inflammation in the brain of people with clinical evidence of neuropsychiatric syndromes, such as mood disorder, chronic pain syndrome, dementia, traumatic brain injury, or substance abuse. The research will also explore whether there is more inflammation in patients with more neuropsychiatric symptoms. Inflammation in the brain will identified by using Positron Emission Tomography (PET) with the radiotracer \[11C\]PBR-28 or \[11C\]ER176.
Recruiting1 award Phase 14 criteria
More about Alan R Prossin, MD
Clinical Trial Related3 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Alan R Prossin, MD has experience with
- PET With Radiotracer [11C]PBR-28
- PET With Radiotracer [11C]PBR-28 ( Or [11C]ER176)
- Anakinra
- Nociceptive Pain Challenge
- Placebo
- HB-adMSCs
Breakdown of trials Alan R Prossin, MD has run
Postprandial Fullness Syndrome
Neuropsychiatric Disorders
Traumatic Brain Injury
Hypoxic-Ischemic Encephalopathy
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Alan R Prossin, MD specialize in?
Alan R Prossin, MD focuses on Postprandial Fullness Syndrome and Neuropsychiatric Disorders. In particular, much of their work with Postprandial Fullness Syndrome has involved treating patients, or patients who are undergoing treatment.
Is Alan R Prossin, MD currently recruiting for clinical trials?
Yes, Alan R Prossin, MD is currently recruiting for 2 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Alan R Prossin, MD has studied deeply?
Yes, Alan R Prossin, MD has studied treatments such as PET with radiotracer [11C]PBR-28, PET with radiotracer [11C]PBR-28 ( or [11C]ER176), anakinra.
What is the best way to schedule an appointment with Alan R Prossin, MD?
Apply for one of the trials that Alan R Prossin, MD is conducting.
What is the office address of Alan R Prossin, MD?
The office of Alan R Prossin, MD is located at: The University of Texas Health Science Center at Houston, Houston, Texas 77030 United States. This is the address for their practice at the The University of Texas Health Science Center at Houston.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.